TIDES 2023: Keynote Address | MarketScreener
Developing 'once-and-done' gene editing medicines to treat cardiovascular disease Sekar Kathiresan, MD CEO, Verve... | May 10, 2023
Source: marketscreener.com
Stay updated with breaking news from About Multiple Cause. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Developing 'once-and-done' gene editing medicines to treat cardiovascular disease Sekar Kathiresan, MD CEO, Verve... | May 10, 2023
Non-invasive, AI-enabled product helps CT readers to accurately, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow portfolio
/PRNewswire/ -- While scientific evidence has supported the health properties of tea's bioactive compounds, there is now guidance on how much of these...